All In MedTech

Device Trial Radar · NCT07753005

HISTOACRYL® Used for Embolization of Thoracoabdominal Artery Bleeding

Observational, Prospective, Multicenter Study on HISTOACRYL® Used for Embolization of Thoracoabdominal Artery Bleeding (TAB)

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

176

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Oct 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Aesculap AGNot on our public-company list
Sponsor type
Industry
First posted
Aug 7, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This observational study will collect information from adult patients in Japan who are treated with Histoacryl® to stop bleeding from arteries in the chest or abdomen, in order to better understand how well the treatment works and how safe it is during routine medical care.

Conditions

  • Hemorrhage
  • Gastrointestinal Hemorrhage
  • Hemoptysis
  • Postpartum Hemorrhage

Interventions

  • Embolization therapyDevice

    Embolization of Thoracoabdominal Artery Bleeding (TAB), excluding "Cardiac blood vessels other than Pulmonary artery", "Endoscopic esophageal varices embolization operations", and "Pulmonary artery malformation".

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Success at 1 Month After Histoacryl® EmbolizationTime frame: 30 ± 10 days after index embolization procedure

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Aichi Cancer Center Hospital

    Nagoya, Aichi-ken, Japan

  • Fujita Health University Hospital

    Toyoake, Aichi-ken, Japan

  • National Cancer Center Hospital East

    Kashiwa, Chiba, Japan

8 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.